Aprea Therapeutics, Inc.
APRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781983
No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Aprea Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 27 | 25 | −2 |
| Shares | 1.71M | 1.59M | −114.4K (−6.7%) |
| Value | $1.11M | $521.3K | −$589.1K (−53.1%) |
New holders (3)
Institutions that held Aprea Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 50,950 | $16.9K | 0.00% |
| Citadel Advisors LLC | 1,276 | $411 | 0.00% |
| Bank of America Corp | 118 | $40 | 0.00% |
Sold out (5)
Institutions that held Aprea Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| BNP Paribas Arbitrage, SA | 61,847 | $40.2K |
| Bridgeway Capital Management, LLC | 20,000 | $13.0K |
| Verition Fund Management LLC | 20,101 | $13.0K |
| Two Sigma Investments, LP | 16,843 | $11.0K |
| StoneX Group Inc. | 12,519 | $8.14K |